AgeX Therapeutics, Inc. (AGE) News

AgeX Therapeutics, Inc. (AGE): $1.31

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 492

in industry

Filter AGE News Items

AGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGE News Highlights

  • AGE's 30 day story count now stands at 2.
  • Over the past 14 days, the trend for AGE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest AGE News From Around the Web

Below are the latest news stories about AgeX Therapeutics Inc that investors may wish to consider to help them evaluate AGE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday Morning

Want to get ready for the trading week?

Sarah Smith on InvestorPlace | April 26, 2021

AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value

Photo by Luis Alvarez/DigitalVision via Getty Images Graphic Source: AgeX Therapeutics, Inc. Introduction: What is AgeX Therapeutics? AgeX Therapeutics, Inc. (NASDAQ: AGE) is a longevity-focused biotechnology company aiming to develop novel therapeutics for human aging and degenerative diseases. Their current pre-clinical programs focus on using vascular endothelial progenitor cells and...

Gunner Laine Hardy on Seeking Alpha | April 14, 2021

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

Yahoo | March 31, 2021

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined company’s pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existin...

Yahoo | March 2, 2021

AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, reported financial and operating results for the third quarter ended September 30, 2020.

Yahoo | November 16, 2020

AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.

Yahoo | August 14, 2020

Reflecting on AgeX Therapeutics' (NYSEMKT:AGE) Share Price Returns Over The Last Year

It is doubtless a positive to see that the AgeX Therapeutics, Inc. (NYSEMKT:AGE) share price has gained some 80% in...

Yahoo | August 7, 2020

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeX’s research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs.

Yahoo | June 16, 2020

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX intends to provide the Exchange staff with a plan by July 1, 2020 advising the Exchange staff of action AgeX ha...

Yahoo | June 5, 2020

AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and ImStem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to derive ImStem’s investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes. AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.

Yahoo | June 2, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5514 seconds.